We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
PPIAL4D
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • PPIAL4D
CANCER LIVER CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
LIHC TCGA LIHC VALIDATION PROTEIN LIHC CPTAC PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Liver cancer
Human cancer
Liver hepatocellular carcinoma
LIVER HEPATOCELLULAR CARCINOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
LIVER HEPATOCELLULAR CARCINOMA (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
LIVER HEPATOCELLULAR CARCINOMA - Protein relative expression (CPTAC)
Number of samples 330
Samples
Sample ID Sample type nRPX
471 Tumor N/A
351 Tumor N/A
472 Normal N/A
231 Tumor N/A
352 Normal N/A
473 Tumor N/A
111 Normal N/A
232 Normal N/A
353 Tumor N/A
474 Normal N/A
112 Tumor N/A
354 Normal N/A
113 Tumor N/A
355 Tumor N/A
114 Normal N/A
356 Normal N/A
477 Tumor N/A
357 Tumor N/A
478 Normal N/A
358 Normal N/A
911 Tumor N/A
912 Normal N/A
913 Tumor N/A
914 Normal N/A
915 Tumor N/A
916 Normal N/A
917 Tumor N/A
918 Normal N/A
481 Tumor N/A
361 Tumor N/A
482 Normal N/A
362 Normal N/A
483 Tumor N/A
363 Tumor N/A
484 Normal N/A
364 Normal N/A
123 Tumor N/A
365 Tumor N/A
124 Normal N/A
366 Normal N/A
487 Tumor N/A
125 Tumor N/A
367 Tumor N/A
488 Normal N/A
126 Normal N/A
368 Normal N/A
127 Tumor N/A
128 Normal N/A
921 Tumor N/A
922 Normal N/A
923 Tumor N/A
924 Normal N/A
925 Tumor N/A
926 Normal N/A
491 Tumor N/A
492 Normal N/A
493 Tumor N/A
131 Tumor N/A
494 Normal N/A
132 Normal N/A
375 Tumor N/A
376 Normal N/A
497 Tumor N/A
135 Tumor N/A
498 Normal N/A
136 Normal N/A
257 Tumor N/A
137 Tumor N/A
258 Normal N/A
138 Normal N/A
813 Tumor N/A
814 Normal N/A
815 Tumor N/A
816 Normal N/A
937 Tumor N/A
817 Tumor N/A
938 Normal N/A
818 Normal N/A
261 Tumor N/A
141 Tumor N/A
262 Normal N/A
383 Tumor N/A
142 Normal N/A
384 Normal N/A
385 Tumor N/A
386 Normal N/A
145 Tumor N/A
387 Tumor N/A
146 Normal N/A
267 Tumor N/A
388 Normal N/A
147 Tumor N/A
268 Normal N/A
148 Normal N/A
943 Tumor N/A
823 Tumor N/A
944 Normal N/A
824 Normal N/A
1022 Normal N/A
1021 Tumor N/A
391 Tumor N/A
271 Tumor N/A
392 Normal N/A
272 Normal N/A
393 Tumor N/A
394 Normal N/A
395 Tumor N/A
396 Normal N/A
277 Tumor N/A
1016 Normal N/A
278 Normal N/A
1015 Tumor N/A
1014 Normal N/A
951 Tumor N/A
1013 Tumor N/A
952 Normal N/A
953 Tumor N/A
954 Normal N/A
713 Tumor N/A
955 Tumor N/A
714 Normal N/A
956 Normal N/A
715 Tumor N/A
957 Tumor N/A
716 Normal N/A
958 Normal N/A
1032 Normal N/A
1031 Tumor N/A
161 Tumor N/A
162 Normal N/A
283 Tumor N/A
284 Normal N/A
285 Tumor N/A
286 Normal N/A
1028 Normal N/A
1027 Tumor N/A
1026 Normal N/A
1025 Tumor N/A
721 Tumor N/A
963 Tumor N/A
722 Normal N/A
964 Normal N/A
723 Tumor N/A
965 Tumor N/A
724 Normal N/A
966 Normal N/A
967 Tumor N/A
968 Normal N/A
727 Tumor N/A
728 Normal N/A
1044 Normal N/A
1043 Tumor N/A
1042 Normal N/A
1041 Tumor N/A
171 Tumor N/A
172 Normal N/A
297 Tumor N/A
298 Normal N/A
851 Tumor N/A
852 Normal N/A
975 Tumor N/A
976 Normal N/A
977 Tumor N/A
615 Tumor N/A
857 Tumor N/A
978 Normal N/A
616 Normal N/A
737 Tumor N/A
858 Normal N/A
617 Tumor N/A
738 Normal N/A
618 Normal N/A
185 Tumor N/A
186 Normal N/A
187 Tumor N/A
188 Normal N/A
981 Tumor N/A
861 Tumor N/A
982 Normal N/A
741 Tumor N/A
862 Normal N/A
983 Tumor N/A
742 Normal N/A
863 Tumor N/A
984 Normal N/A
1046 Normal N/A
743 Tumor N/A
864 Normal N/A
1045 Tumor N/A
744 Normal N/A
865 Tumor N/A
745 Tumor N/A
866 Normal N/A
746 Normal N/A
867 Tumor N/A
868 Normal N/A
627 Tumor N/A
628 Normal N/A
191 Tumor N/A
192 Normal N/A
195 Tumor N/A
196 Normal N/A
873 Tumor N/A
874 Normal N/A
513 Tumor N/A
755 Tumor N/A
514 Normal N/A
635 Tumor N/A
756 Normal N/A
877 Tumor N/A
515 Tumor N/A
636 Normal N/A
878 Normal N/A
516 Normal N/A
517 Tumor N/A
518 Normal N/A
881 Tumor N/A
882 Normal N/A
641 Tumor N/A
883 Tumor N/A
642 Normal N/A
884 Normal N/A
523 Tumor N/A
524 Normal N/A
525 Tumor N/A
526 Normal N/A
647 Tumor N/A
527 Tumor N/A
648 Normal N/A
528 Normal N/A
411 Tumor N/A
412 Normal N/A
533 Tumor N/A
413 Tumor N/A
534 Normal N/A
414 Normal N/A
535 Tumor N/A
777 Tumor N/A
415 Tumor N/A
536 Normal N/A
778 Normal N/A
416 Normal N/A
537 Tumor N/A
538 Normal N/A
661 Tumor N/A
662 Normal N/A
421 Tumor N/A
663 Tumor N/A
422 Normal N/A
664 Normal N/A
785 Tumor N/A
423 Tumor N/A
665 Tumor N/A
786 Normal N/A
424 Normal N/A
545 Tumor N/A
666 Normal N/A
425 Tumor N/A
546 Normal N/A
426 Normal N/A
427 Tumor N/A
428 Normal N/A
671 Tumor N/A
672 Normal N/A
431 Tumor N/A
311 Tumor N/A
432 Normal N/A
553 Tumor N/A
312 Normal N/A
433 Tumor N/A
554 Normal N/A
313 Tumor N/A
434 Normal N/A
314 Normal N/A
435 Tumor N/A
436 Normal N/A
557 Tumor N/A
558 Normal N/A
563 Tumor N/A
443 Tumor N/A
564 Normal N/A
685 Tumor N/A
444 Normal N/A
686 Normal N/A
445 Tumor N/A
446 Normal N/A
567 Tumor N/A
447 Tumor N/A
568 Normal N/A
327 Tumor N/A
448 Normal N/A
328 Normal N/A
571 Tumor N/A
451 Tumor N/A
572 Normal N/A
331 Tumor N/A
452 Normal N/A
573 Tumor N/A
211 Tumor N/A
332 Normal N/A
574 Normal N/A
695 Tumor N/A
212 Normal N/A
696 Normal N/A
213 Tumor N/A
455 Tumor N/A
697 Tumor N/A
214 Normal N/A
456 Normal N/A
698 Normal N/A
217 Tumor N/A
218 Normal N/A
461 Tumor N/A
341 Tumor N/A
462 Normal N/A
221 Tumor N/A
342 Normal N/A
463 Tumor N/A
222 Normal N/A
343 Tumor N/A
464 Normal N/A
223 Tumor N/A
344 Normal N/A
465 Tumor N/A
224 Normal N/A
466 Normal N/A
467 Tumor N/A
468 Normal N/A
227 Tumor N/A
228 Normal N/A
Show allShow less
LIVER CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA058345
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Carcinoma, Hepatocellular, NOS
Cholangiocarcinoma

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org